BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 27416955)

  • 21. Tumor localization of an anti-TGF-β antibody and its effects on gliomas.
    Hülper P; Schulz-Schaeffer W; Dullin C; Hoffmann P; Harper J; Kurtzberg L; Lonning S; Kugler W; Lakomek M; Erdlenbruch B
    Int J Oncol; 2011 Jan; 38(1):51-9. PubMed ID: 21109925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.
    Saidi A; Hagedorn M; Allain N; Verpelli C; Sala C; Bello L; Bikfalvi A; Javerzat S
    Int J Cancer; 2009 Sep; 125(5):1054-64. PubMed ID: 19431143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo.
    Atzori MG; Tentori L; Ruffini F; Ceci C; Bonanno E; Scimeca M; Lacal PM; Graziani G
    J Pharmacol Exp Ther; 2018 Jan; 364(1):77-86. PubMed ID: 29025978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioluminescence and MR Imaging of the Safety and Efficacy of Vascular Disruption in Gliomas.
    Folaron M; Seshadri M
    Mol Imaging Biol; 2016 Dec; 18(6):860-869. PubMed ID: 27160251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model.
    Ugur HC; Ramakrishna N; Bello L; Menon LG; Kim SK; Black PM; Carroll RS
    J Neurooncol; 2007 Jul; 83(3):267-75. PubMed ID: 17310267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
    Miletic H; Niclou SP; Johansson M; Bjerkvig R
    Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007.
    Towner RA; Gillespie DL; Schwager A; Saunders DG; Smith N; Njoku CE; Krysiak RS; Larabee C; Iqbal H; Floyd RA; Bourne DW; Abdullah O; Hsu EW; Jensen RL
    Neuro Oncol; 2013 Mar; 15(3):330-40. PubMed ID: 23328810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas.
    Argyriou AA; Giannopoulou E; Kalofonos HP
    Oncology; 2009; 77(1):1-11. PubMed ID: 19439998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiogenesis and antiangiogenic therapy for malignant gliomas.
    Takano S; Kamiyama H; Tsuboi K; Matsumura A
    Brain Tumor Pathol; 2004; 21(2):69-73. PubMed ID: 15700836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.
    Kunkel P; Ulbricht U; Bohlen P; Brockmann MA; Fillbrandt R; Stavrou D; Westphal M; Lamszus K
    Cancer Res; 2001 Sep; 61(18):6624-8. PubMed ID: 11559524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin.
    Li XQ; Ouyang ZG; Zhang SH; Liu H; Shang Y; Li Y; Zhen YS
    Cancer Biol Ther; 2014 Apr; 15(4):398-408. PubMed ID: 24424202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma.
    Ali MM; Janic B; Babajani-Feremi A; Varma NR; Iskander AS; Anagli J; Arbab AS
    PLoS One; 2010 Jan; 5(1):e8727. PubMed ID: 20090952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model.
    Luo Y; Jiang F; Cole TB; Hradil VP; Reuter D; Chakravartty A; Albert DH; Davidsen SK; Cox BF; McKeegan EM; Fox GB
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):911-21. PubMed ID: 22080168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
    Dai B; Qi N; Li J; Zhang G
    Biochem Biophys Res Commun; 2018 Jul; 501(4):871-876. PubMed ID: 29758196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization.
    Goldbrunner RH; Bendszus M; Wood J; Kiderlen M; Sasaki M; Tonn JC
    Neurosurgery; 2004 Aug; 55(2):426-32; discussion 432. PubMed ID: 15271251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
    Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development.
    Hong YK; Chung DS; Joe YA; Yang YJ; Kim KM; Park YS; Yung WK; Kang JK
    Clin Cancer Res; 2000 Aug; 6(8):3354-60. PubMed ID: 10955823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
    Rapisarda A; Hollingshead M; Uranchimeg B; Bonomi CA; Borgel SD; Carter JP; Gehrs B; Raffeld M; Kinders RJ; Parchment R; Anver MR; Shoemaker RH; Melillo G
    Mol Cancer Ther; 2009 Jul; 8(7):1867-77. PubMed ID: 19584228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The anti-angiogenic role of soluble-form VEGF receptor in malignant gliomas.
    Takano S; Ishikawa E; Matsuda M; Sakamoto N; Akutsu H; Yamamoto T; Matsumura A
    Int J Oncol; 2017 Feb; 50(2):515-524. PubMed ID: 28000842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.